BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
18 |
0.69 |
x 10E6 cells/ml |
0.05 |
0.23 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU |
111101 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
21 |
2.1 |
x 10E6 cells/ml |
0.08 |
0.36 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
111105 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
18 |
2267.0 |
cells/ul |
74.25 |
315.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
111093 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
91 days-105 days |
18 |
0.96 |
x 1000 cells/ul |
0.06 |
0.25 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU |
111110 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
18 |
1.23 |
x 10E6 cells/ml |
0.05 |
0.23 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
111103 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
111 days-125 days |
18 |
0.3 |
x 1000 cells/ul |
0.08 |
0.36 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU |
111111 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
111 days-125 days |
18 |
2.22 |
x 1000 cells/ul |
0.06 |
0.26 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
111113 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
21 |
1215.0 |
cells/ul |
87.07 |
399.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
111094 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
21 |
2.0 |
x 10E6 cells/ml |
0.11 |
0.51 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
111104 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
91 days-105 days |
18 |
1.88 |
x 1000 cells/ul |
0.07 |
0.29 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
111112 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
111 days-125 days |
21 |
4.5 |
x 1000 cells/ul |
0.23 |
1.05 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
111115 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
21 |
3664.0 |
cells/ul |
56.74 |
260.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
111095 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
18 |
0.43 |
x 10E6 cells/ml |
0.02 |
0.11 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU |
111100 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
18 |
1.1 |
x 10E6 cells/ml |
0.02 |
0.09 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
111102 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
18 |
987.0 |
cells/ul |
23.81 |
101.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
111092 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
18 |
641.0 |
cells/ul |
161.46 |
685.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU |
111091 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
18 |
588.0 |
cells/ul |
49.73 |
211.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU |
111090 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
91 days-105 days |
21 |
3.39 |
x 1000 cells/ul |
0.16 |
0.72 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
111114 |
3196 |